[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.247.205. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Medical News & Perspectives
August 25, 2010

As Use of Foreign Drug Trials Grows, FDA Oversight May Not Be Keeping Up

JAMA. 2010;304(8):843-844. doi:10.1001/jama.2010.1194

The increasing reliance on foreign clinical trials for testing new drugs has led to concerns about the ability of the US Food and Drug Administration (FDA) to monitor such research, according to a US government report.

The report, issued June 22 by the US Department of Health and Human Services' Office of Inspector General (OIG), noted that in fiscal year 2008, 80% of marketing applications for drugs and biologics approved for US use contained data from foreign clinical trials, and more than half of clinical trial participants and sites were located outside of the country. But the OIG found that the FDA was able to inspect only 0.7% of such trial locations, compared with 1.9% of domestic clinical trial sites (http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf). The OIG also reported that reliance on foreign trials by pharmaceutical interests appears likely to increase.

First Page Preview View Large
First page PDF preview
First page PDF preview
×